vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and XPEL, Inc. (XPEL). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $122.3M, roughly 1.6× XPEL, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 13.7%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 16.5%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

XPEL, Inc. is a global provider of high-performance surface protection solutions primarily for automotive use. Core offerings include paint protection films, window tints, and ceramic coatings, serving vehicle owners, dealerships, and professional installers across North America, Europe, and Asia Pacific.

AXSM vs XPEL — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.6× larger
AXSM
$191.2M
$122.3M
XPEL
Growing faster (revenue YoY)
AXSM
AXSM
+43.7% gap
AXSM
57.4%
13.7%
XPEL
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
48.1%
16.5%
XPEL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AXSM
AXSM
XPEL
XPEL
Revenue
$191.2M
$122.3M
Net Profit
$13.4M
Gross Margin
41.9%
Operating Margin
-33.1%
12.7%
Net Margin
11.0%
Revenue YoY
57.4%
13.7%
Net Profit YoY
50.7%
EPS (diluted)
$0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
XPEL
XPEL
Q1 26
$191.2M
Q4 25
$196.0M
$122.3M
Q3 25
$171.0M
$125.4M
Q2 25
$150.0M
$124.7M
Q1 25
$121.5M
$103.8M
Q4 24
$118.8M
$107.5M
Q3 24
$104.8M
$112.9M
Q2 24
$87.2M
$109.9M
Net Profit
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
$-28.6M
$13.4M
Q3 25
$-47.2M
$12.9M
Q2 25
$-48.0M
$16.3M
Q1 25
$-59.4M
$8.6M
Q4 24
$-74.9M
$8.9M
Q3 24
$-64.6M
$14.9M
Q2 24
$-79.3M
$15.0M
Gross Margin
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
41.9%
Q3 25
41.8%
Q2 25
42.9%
Q1 25
42.3%
Q4 24
40.6%
Q3 24
42.5%
Q2 24
43.5%
Operating Margin
AXSM
AXSM
XPEL
XPEL
Q1 26
-33.1%
Q4 25
-13.8%
12.7%
Q3 25
-27.0%
13.4%
Q2 25
-24.5%
15.5%
Q1 25
-46.9%
10.7%
Q4 24
-61.1%
11.5%
Q3 24
-59.8%
16.3%
Q2 24
-89.5%
17.5%
Net Margin
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
-14.6%
11.0%
Q3 25
-27.6%
10.3%
Q2 25
-32.0%
13.1%
Q1 25
-48.9%
8.3%
Q4 24
-63.1%
8.3%
Q3 24
-61.7%
13.2%
Q2 24
-91.0%
13.7%
EPS (diluted)
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
$-0.55
$0.48
Q3 25
$-0.94
$0.47
Q2 25
$-0.97
$0.59
Q1 25
$-1.22
$0.31
Q4 24
$-1.54
$0.33
Q3 24
$-1.34
$0.54
Q2 24
$-1.67
$0.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
XPEL
XPEL
Cash + ST InvestmentsLiquidity on hand
$305.1M
$50.9M
Total DebtLower is stronger
$70.0M
Stockholders' EquityBook value
$280.3M
Total Assets
$713.6M
$382.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
XPEL
XPEL
Q1 26
$305.1M
Q4 25
$322.9M
$50.9M
Q3 25
$325.3M
$64.5M
Q2 25
$303.0M
$49.6M
Q1 25
$300.9M
$23.5M
Q4 24
$315.4M
$22.1M
Q3 24
$327.3M
$21.0M
Q2 24
$315.7M
$15.0M
Total Debt
AXSM
AXSM
XPEL
XPEL
Q1 26
$70.0M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
$88.3M
$280.3M
Q3 25
$73.7M
$269.3M
Q2 25
$73.1M
$255.7M
Q1 25
$53.2M
$235.5M
Q4 24
$57.0M
$225.5M
Q3 24
$92.9M
$218.7M
Q2 24
$102.9M
$201.9M
Total Assets
AXSM
AXSM
XPEL
XPEL
Q1 26
$713.6M
Q4 25
$689.8M
$382.5M
Q3 25
$669.3M
$387.7M
Q2 25
$639.8M
$318.1M
Q1 25
$596.7M
$294.8M
Q4 24
$568.5M
$285.6M
Q3 24
$561.5M
$273.0M
Q2 24
$548.2M
$261.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
XPEL
XPEL
Operating Cash FlowLast quarter
$2.7M
Free Cash FlowOCF − Capex
$1.6M
FCF MarginFCF / Revenue
1.3%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
0.20×
TTM Free Cash FlowTrailing 4 quarters
$62.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
$-18.7M
$2.7M
Q3 25
$1.0M
$33.2M
Q2 25
$-32.4M
$27.9M
Q1 25
$-43.4M
$3.2M
Q4 24
$-26.2M
$6.3M
Q3 24
$-18.6M
$19.6M
Q2 24
$-30.1M
$26.9M
Free Cash Flow
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
$-18.7M
$1.6M
Q3 25
$988.0K
$32.2M
Q2 25
$-32.4M
$26.9M
Q1 25
$-43.7M
$2.2M
Q4 24
$-26.2M
$4.7M
Q3 24
$-18.7M
$18.3M
Q2 24
$-30.2M
$25.1M
FCF Margin
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
-9.6%
1.3%
Q3 25
0.6%
25.6%
Q2 25
-21.6%
21.6%
Q1 25
-36.0%
2.1%
Q4 24
-22.1%
4.4%
Q3 24
-17.9%
16.2%
Q2 24
-34.6%
22.8%
Capex Intensity
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
0.0%
0.9%
Q3 25
0.0%
0.8%
Q2 25
0.0%
0.8%
Q1 25
0.3%
1.0%
Q4 24
0.0%
1.5%
Q3 24
0.1%
1.1%
Q2 24
0.1%
1.6%
Cash Conversion
AXSM
AXSM
XPEL
XPEL
Q1 26
Q4 25
0.20×
Q3 25
2.56×
Q2 25
1.71×
Q1 25
0.38×
Q4 24
0.71×
Q3 24
1.31×
Q2 24
1.79×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Product sales, net$189.4M99%
Royalty revenue and milestone revenue$1.8M1%

XPEL
XPEL

Products$90.9M74%
Service Revenue Installation Labor$23.8M19%
Service Revenue Cutbank Credits$4.1M3%
Service Revenue Software$2.2M2%

Related Comparisons